Stereotactic body radiation therapy for unbiopsied early-stage lung cancer: A multi-institutional analysis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 4, 2014, Pages 337-342

  Harkenrider, Matthew M ^a   Bertke, Matthew H ^a   Dunlap, Neal E ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Lung cancer; Medically inoperable; SBRT; Stereotactic; Unbiopsied

Indexed keywords

AGED; BIOPSY; DOSE FRACTIONATION; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOSURGERY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84905083666     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318277d822     Document Type: Article

References (36)

1. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2007/. Accessed March 26, 2012.
2. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995; 109: 120-129.
3. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995; 60: 615-622; discussion 622-613.
4. Armstrong JG, Minsky BD. Radiation therapy for medically inoperable stage I and II non-small cell lung cancer. Cancer Treat Rev. 1989; 16: 247-255.
5. Dosoretz DE, Katin MJ, Blitzer PH, et al. Medically inoperable lung carcinoma: the role of radiation therapy. Semin Radiat Oncol. 1996; 6: 98-104.
6. Kaskowitz L, Graham MV, Emami B, et al. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 1993; 27: 517-523.
7. Onishi H, Kuriyama K, Komiyama T, et al. Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: patient self-controlled breathhold and beam switching using a combination of linear accelerator and CT scanner. Lung Cancer. 2004; 45: 45-55.
8. Nagata Y, Takayama K, Matsuo Y, et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005; 63: 1427-1431.
9. McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005; 63: 1010-1015.
10. Xia T, Li H, Sun Q, et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006; 66: 117-125.
11. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys. 2009; 75: 677-682.
12. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303: 1070-1076.
13. Deppen S, Putnam JB Jr, Andrade G, et al. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg. 2011; 92: 428-432; discussion 433.
14. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable earlystage lung cancer. J Clin Oncol. 2006; 24: 4833-4839.
15. Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys. 2010; 37: 4078-4101.
16. RTOG 0915 Protocol Information. Available at: http://www.rtog. org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study = 0915. Accessed March 26, 2012.
17. Priola AM, Priola SM, Cataldi A, et al. Diagnostic accuracy and complication rate of CT-guided fine needle aspiration biopsy of lung lesions: a study based on the experience of the cytopathologist. Acta Radiol. 2010; 51: 527-533.
18. Laspas F, Roussakis A, Efthimiadou R, et al. Percutaneous CTguided fine-needle aspiration of pulmonary lesions: results and complications in 409 patients. J Med Imaging Radiat Oncol. 2008; 52: 458-462.
19. Chakrabarti B, Earis JE, Pandey R, et al. Risk assessment of pneumothorax and pulmonary haemorrhage complicating percutaneous co-axial cutting needle lung biopsy. Respir Med. 2009; 103: 449-455.
20. Chojniak R, Isberner RK, Viana LM, et al. Computed tomography guided needle biopsy: experience from 1, 300 procedures. Sao Paulo Med J. 2006; 124: 10-14.
21. Dewan NA, Gupta NC, Redepenning LS, et al. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest. 1993; 104: 997-1002.
22. Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxyglucose- positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med. 1996; 153: 417-421.
23. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001; 285: 914-924.
24. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002; 359: 1388-1393.
25. Belgers EH, Siebenga J, Bosch AM, et al. Complete video-assisted thoracoscopic surgery lobectomy and its learning curve. A single center study introducing the technique in The Netherlands. Interact Cardiovasc Thorac Surg. 2010; 10: 176-180.
26. Guckenberger M, Kestin LL, Hope AJ, et al. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer? J Thorac Oncol. 2012; 7: 542-551.
27. Baumann P, Nyman J, Hoyer M, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009; 27: 3290-3296.
28. Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer. 2010; 68: 72-77.
29. Beitler JJ, Badine EA, El-Sayah D, et al. Stereotactic body radiation therapy for nonmetastatic lung cancer: an analysis of 75 patients treated over 5 years. Int J Radiat Oncol Biol Phys. 2006; 65: 100-106.
30. Lagerwaard FJ, Haasbeek CJ, Smit EF, et al. Outcomes of riskadapted fractionated stereotactic radiotherapy for stage I nonsmall- cell lung cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 685-692.
31. Baumann P, Nyman J, Lax I, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006; 45: 787-795.
32. Inoue T, Shimizu S, Onimaru R, et al. Clinical outcomes of stereotactic body radiotherapy for small lung lesions clinically diagnosed as primary lung cancer on radiologic examination. Int J Radiat Oncol Biol Phys. 2009; 75: 683-687.
33. Verstegen NE, Lagerwaard FJ, Haasbeek CJ, et al. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol. 2011; 101: 250-254.
34. Takeda A, Kunieda E, Sanuki N, et al. Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer. Lung Cancer. 2012; 77: 77-82.
35. Haasbeek CJ, Palma D, Visser O, et al. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol. 2012; 23: 2743-2747.
36. Stephans KL, Djemil T, Reddy CA, et al. A comparison of two stereotactic body radiation fractionation schedules for medically inoperable stage I non-small cell lung cancer: the Cleveland Clinic experience. J Thorac Oncol. 2009; 4: 976-982.